Mindset’s next generation 5-MeO-DMT drug candidates have shown a significant decrease in serotonergic toxicity; results reaffirm superior efficacy and safety TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation…

Source

Previous articleField Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians
Next articleRed Light Closes Acquisition of Mera Life Sciences and Files Quarterly Financial Statements